Stent Manufacturers Proliferate, Create Market Pressure

As a follow-up to the Feb. 2 post regarding the settlement of patent disputes between J&J and Boston Scientific, a big driver of that settlement is indeed the level of competitiveness that has come to characterize the coronary stent market.  The situation in 2010 is a far cry from the situation in 2003/2004, when the patent dispute erupted and when J&J and Boston Scientific were really the only drug-eluting stent (DES) competitors in town.  A raft of other DES manufacturers, big and small, have emerged who now pose a real challenge (like Abbott's Xience stent) to TAXUS and CYPHER dominance.  Moreover, bare metal stents, while holding a lesser position due to differences in clinical performance compared to DES (some real, some just perceived), are still garnering caseload from interventional cardiologists and others concerned about late stage thrombosis, device cost, or other limitations of DES.  Add to this the prospect of bioabsorbable stents, which may not be as disruptive to the market status quo as DES were when they entered the fray, but which will nonetheless cause a definite shift in caseload.

The number of competitors spanning all stent and other anti-restenosis options is evidence enough of the pressure Boston Scientific had to reach a settlement so that they could focus on the market. 

For evidence, see the list of companies profiled in our Worldwide Market for Coronary Stents report #C245:

Aachen Resonance GmbH; Abbott Vascular; AdvanSource Biomaterials Corporation; Aeon Bioscience; Allvivo Vascular, Inc.; Amaranth Medical, Inc.; amg International GmbH; Arterial Remodeling Technologies (ART); Arterius Ltd.; Atrium Medical; Avantec Vascular; B. Braun Melsungen; Balton Ltd.; Bioabsorbable Therapeutics, Inc.; Bioring SA; Biosensors International; Biotronik; Blue Medical Devices B.V.; Boston Scientific; Caliber Therapeutics; Cappella Inc.; CardioMind, Inc.; CeloNova BioSciences, Inc.; CID S.r.l. (Formerly Sorin Vascular Therapy); Cinvention AG (Formerly Blue Membranes); CorNova; CV Therapeutics/Gilead Inc.; Devax; DISA Vascular; Elixir Medical Corp.; Estracure Inc.; eucatech AG; Genesis Technologies, LLC; Global Therapeutics (Cook Medical); Hexacath; ICON Interventional (Formerly ICON Medical Corp.); InspireMD; InTek Technology; Invatec s.r.l.; ITGI Medical Ltd.; Johnson & Johnson (Cordis, Conor Medsystems); JW Medical Systems / Biosensors International; Kaneka Corporation; Kyoto Medical Planning Co., Ltd.; Lepu Medical; Lutonix, Inc.; Medinol/ARIAD Pharmaceuticals; Medlogics Device Corporation (MDC); Medtronic Vascular; Miami Cardiovascular Innovations; Micell Technologies; MicroPort Scientific Corporation; Minvasys; MIV Therapeutics; mNEMOSCIENCE GmbH; MoBeta, Inc.; NanoInterventions, LLC; Neovasc, Inc.; Nexeon MedSystems, Inc.; Opto Circuits (India) Ltd.; 4.60.1 EuroCor GmbH; OrbusNeich; Palmaz Scientific, Inc.; Picarus NV; Possis Medical (Bayer); Prescient Medical; Relisys Medical Devices; REVA Medical; Sahajanand Medical Technologies; Stentys SAS; Sterling Vascular; Terumo; Translumina; TriReme Medical; Tryton Medical; Vascular Concepts; VasoTech, Inc.; X-Cell Medical

Leave a Reply